Patel Shivani, Marchetti Nathaniel, Ganjian Haleh, Yu Daohai, Kelsen Steven G, Criner Gerard J, Sajjan Umadevi S
Center for Inflammation and Lung Research, Temple University, Philadelphia, PA 19140, United States.
Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA 19140, United States.
Pharmacol Res Nat Prod. 2025;7. doi: 10.1016/j.prenap.2025.100252. Epub 2025 May 5.
Airway inflammation plays a major role in the development and progression of chronic obstructive pulmonary disease (COPD). Quercetin, which has potent antioxidant and anti-inflammatory properties reduces lung inflammation in mice displaying COPD-like lung disease. Previously we showed that quercetin was safely tolerated up to 2000 mg/day. We conducted a pilot Phase II clinical trial to examine the effects of quercetin on inflammation in COPD patients.
Fourteen COPD patients with ≥ 10 pack-year smoking history and CRP > 3.0 mg/L were randomized in 1:2 ratio to either placebo or quercetin 2000 mg/day for 6 months. Blood and bronchoalveolar lavage fluid (BALF) were collected at baseline and 6 months post-treatment. The reduction of inflammatory and oxidative stress biomarkers in BALF and blood were expressed as change from baseline. Safety of quercetin was assessed based on FEV and blood tests.
Plasma quercetin levels significantly increased after treatment in only quercetin group. The levels of IL-8, IL-1β, and 8-isoprostane in the BAL and serum SP-D were significantly different from baseline in patients treated with quercetin, but not placebo. The patient-reported disease symptoms showed lowering trend in quercetin-treated group. No study drug-related adverse events were observed as assessed by comprehensive metabolic panel and FEV.
Oral treatment with quercetin was safely and well-tolerated by COPD patients. Quercetin treatment reduced some lung and serum inflammatory biomarkers in COPD. Further prospective studies are necessary to confirm the anti-inflammatory and antioxidant effects of quercetin in COPD patients and to determine if quercetin offers any clinical benefit.
气道炎症在慢性阻塞性肺疾病（COPD）的发生和发展中起主要作用。具有强大抗氧化和抗炎特性的槲皮素可减轻表现出COPD样肺部疾病的小鼠的肺部炎症。此前我们表明，槲皮素每日剂量达2000毫克时耐受性良好。我们进行了一项II期临床试验，以研究槲皮素对COPD患者炎症的影响。
14名吸烟史≥10包年且CRP>3.0毫克/升的COPD患者按1:2的比例随机分为安慰剂组或每日服用2000毫克槲皮素组，为期6个月。在基线和治疗后6个月收集血液和支气管肺泡灌洗液（BALF）。BALF和血液中炎症和氧化应激生物标志物的减少以相对于基线的变化表示。基于FEV和血液检测评估槲皮素的安全性。
仅槲皮素组治疗后血浆槲皮素水平显著升高。槲皮素治疗的患者BAL中的IL-8、IL-1β和8-异前列腺素水平以及血清SP-D与基线有显著差异，而安慰剂组无此差异。患者报告的疾病症状在槲皮素治疗组呈下降趋势。综合代谢指标和FEV评估未观察到与研究药物相关的不良事件。
COPD患者口服槲皮素安全且耐受性良好。槲皮素治疗可降低COPD患者的一些肺部和血清炎症生物标志物。需要进一步的前瞻性研究来证实槲皮素对COPD患者的抗炎和抗氧化作用，并确定槲皮素是否具有任何临床益处。
